

Highlights

The Action's 4th Grant Period (GP) started beginning of May 2016 and will finally end in April 2017. The COST Action activities during the course of the Action are all shown in our website eupancreas.com. Find below a brief summary of the **main activities carried out by the WGs**:

245 members from:

- 22 EU countries
- 5 EU gov & non-gov institutions
- 3 Biotech companies (SME)
- 1 Pharma company

	WG1	WG2	WG3	WG4
Training schools & workshops	Pathology European pancreas biobank Cancer Epidemiology Panc4 PancreOS registry	Capita selecta Complex Diseases Cancer Genomics Interactions in complex disease analysis	London Pancreas Pancreas cystic tumors Genomic Medicine	Issues in pancreatology PancreOS (registry) EAMP conference Health Forum Gastein
STSMs	6+2 with WG4	6	7 + 1 with WG4	5 + 3 with WG1 or WG3
Research lines/tools	Epidemiology & clinical questionnaires (PancreOS) SOPs for biobanking	Resources and omics databases	Definition of risk population Registry for biomaterial Study group IPMN	Barriers in Access to personalised Medicine report
WG meetings	Madrid, Heidelberg, Milan, Cluj-Napoca, Toledo, Liege	Barcelona, Liege, Cluj-Napoca Madrid, Toledo, Heidelberg	Madrid, Liverpool, Toledo, Cluj-Napoca, Liege, London	Madrid, Cluj-Napoca, Toledo, Liege, Toledo
Dissemination	9 articles Podcast, web, twitter	2 book chapters, 2 articles Podcast, web, twitter	4 articles Podcast, web, twitter	White Paper, 4 articles Podcast, web, twitter
Grant applications	1 H2020	--	2 H2020	--

Now we have established an European Pancreatic Research Community, motivated by EUPancreas, we will move onto a sustainable group, working towards filling the pancreatic cancer research needs in Europe. One of the areas already identified for further action is the creation of a Pancreatic Cancer Research Stream, under the umbrella of Pancreatic Cancer Europe.

PANCREATIC CANCER EUROPE (PCE) is an European multi-stakeholder platform which aims to bring together experts from all over Europe including academics, physicians, politicians, patient groups, journalists and industry. The platform was created in 2014 and became a legal entity in 2016. They work towards the development of targeted European and national policies on pancreatic cancer, to raise awareness of the condition at national level, to improve its diagnosis, to foster data collection, and to support research. More information is shown at the PCE website: pancreaticcancereurope.eu

A joint EUPancreas + PCE meeting will be celebrated 12th April 2017 in Brussel (Belgium), where "Pancreatic cancer research priorities" in Europe will be discussed among researchers, stakeholders and health policy makers. The meeting's report and key information will be uploaded and distributed through eupancreas.com & pancreaticcancereurope.eu



The EUPancreas SC thanks you all for your contributions to the Action that represents the start of a longer term effort under the umbrella of PCE. Looking forward to continue building an even larger and stronger European pancreatic cancer research community!

Early Career Investigators (ECIs):

Overall, 26 STMs were awarded by the COST Action EUPancreas. The list of awardees and summary of the research stays are available at eupancreas.com/stsm. EUPancreas has enabled us to give young researchers an opportunity to get in touch with the European pancreatic cancer community, thereby fostering the new generation of pancreatic cancer research professionals. Ways are sought to continue to support this initiative in Europe. Information about short-term research stays will be posted at eupancreas.com and pancreaticcancereurope.eu.

Upcoming scientific Events:

- ☐ **12 April: Pancreatic Cancer Research Meeting.** Brussel, Belgium
- ☐ **27 to 29 March:** World Congress on Cancer. London, UK
- ☐ **2 to 5 May:** World Pancreatic Cancer Coalition Annual Meeting. Montreal, Canada
- ☐ **28 June to 1 July:** Meeting of the European Pancreatic Cancer Club (EPC meeting). Budapest, Hungary
- ☐ **28 June to 1 July:** 19th World Congress on Gastrointestinal cancer (ESMO meeting). Barcelona, Spain
- ☐ **2 to 6 June:** 53rd ASCO meeting. Chicago, USA

New pancreatic cancer-related studies:

Publications acknowledging the "COST Action BM1204 EU-Pancreas"

- 📖 Malvezzi M, et al. European cancer mortality predictions for the year 2017, with focus on lung cancer. *Ann Oncol.* 2017 Feb 21. [Epub ahead of print]
- 📖 Villanueva E, et al. Translational reprogramming in tumour cells can generate oncoselectivity in viral therapies *Nat Commun.* 2017 Mar 16;8:14833.
- 📖 Vasen H, et al. Benefit of Surveillance for Pancreatic Cancer in High-Risk Individuals: Outcome of Long-Term Prospective Follow-Up Studies From Three European Expert Centers. *J Clin Oncol.* 2016 Jun 10;34(17):2010-9.

Other publications:

- 📖 Schlitter AM, et al. Molecular, morphological and survival analysis of 177 resected pancreatic ductal adenocarcinomas: Identification of prognostic subtypes. *Sci Rep.* 2017 Feb 17;7:41064. [Epub ahead of print]
- 📖 Choi SH, et al. Progression of Unresected Intraductal Papillary Mucinous Neoplasms of the Pancreas to Cancer: A Systematic Review and Meta-analysis. *Clin Gastroenterol Hepatol.* 2017 Mar 22. [Epub ahead of print]
- 📖 Mayerle J, et al. Metabolic biomarker signature to differentiate pancreatic ductal adenocarcinoma from chronic pancreatitis. *Gut.* 2017 Jan 20. [Epub ahead of print]